Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices 34025 

approaches to block HIV transmission 

and to treat infected people. A small 

animal expressing both human CCR5 

along with human CD4 supports entry 

of HIV into target cells, a necessary 

hurdle that must be overcome for 

development of a small animal model 

(e.g. transgenic mouse, rat, rabbit, mink) 

to study HIV infection and its 

inhibition. 

The invention embodies the CCR5 

genetic sequence, cell lines and 

transgenic animals, the cells of which 

coexpress human CD4 and CCR5, and 

which may represent valuable tools for 

the study of HIV infection and for 

screening anti-HIV agents. The 

invention also embodies anti-CCR5 

agents that block HIV env-mediated 

membrane fusion associated with HIV 

entry into human CD4-positive target 

cells or between HIV-infected cells and 

uninfected human CD4-positive target 

cells. 

Inventors: Christophe Combadiere, Yu 

Feng, Ghalib Alkahatib, Edward A. 

Berger, Philip M. Murphy, Christopher 

C. Broder, Paul E. Kennedy (NIAID). 

Publication: This technology was 

reported in Alkhatib et al., ‘‘CC CKR5: 

a RANTES, MIP–1alpha, MIP–1beta 

receptor as a fusion cofactor for 

macrophage-tropic HIV–1,’’ Science 

1996 Jun 28;272(5270):1955–1958. 

Patent Status: 

U.S. Provisional Application No. 60/ 

018,508 filed 28 May 1996 (HHS 

Reference No. E–090–1996/0–US–01) 

U.S. Patent Application No. 08/864,458 

filed 28 May 1997 (HHS Reference 

No. E–090–1996/0–US–04) 

U.S. Patent No. 7,151,087 issued 19 Dec 

2006 (HHS Reference No. E–090–

1996/0–US–06) 

U.S. Patent Application No. 10/439,845 

filed 15 May 2003 (HHS Reference 

No. E–090–1996/0–US–05) 

U.S. Patent Application No. 10/846,185 

filed 14 May 2004 (HHS Reference 

No. E–090–1996/0–US–07) 

U.S. Patent Application No. 11/594,375 

filed 07 Nov 2006 (HHS Reference No. 

E–090–1996/0–US–08) 

PCT Application No. PCT/US97/09586 

filed 28 May 1997 (HHS Reference 

No. E–090–1996/0–PCT–02) 

European Patent Application No. 

97929777.7 filed 28 May 1997 (HHS 

Reference No. E–090–1996/0–EP–03) 

Licensing Status: The technology is 

available for exclusive or nonexclusive 

licensing. 

Licensing Contact: Peter Soukas; 301/ 

435–4646; soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Laboratory of Molecular 

Immunology and Laboratory of Viral 

Diseases are seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize CCR5-related products. 

Please contact Philip Murphy (301–496–

8616, pmm@nih.gov) or Edward Berger 

(301–402–2481, 

edward_berger@nih.gov) for more 

information. 

Dated: June 11, 2007. 

Steven M. Ferguson, 

Director,Division of Technology Development 

and Transfer,Office of Technology 

Transfer,National Institutes of Health. 

[FR Doc. E7–11854 Filed 6–19–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes on Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Special 

Review. 

Date: June 28, 2007. 

Time: 1:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

(Telephone Conference Call). 

Contact Person: Kesinee Nimit, MD, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

NIH, DHHS, Room 220, MSC 8401, 6101 

Executive Boulevard, Bethesda, MD 20892–

8401, (301) 435–1432. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

Pathway to Independence Award. 

Date: July 11, 2007. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

(Telephone Conference Call). 

Contact Person: Gerald L. McLaughin, PhD, 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Boulevard, Bethesda, 

MD 20892–8401, (301) 402–6626. 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, NIDA–

K Conflicts. 

Date: July 17, 2007. 

Time: 5 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Bethesda, 8120 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Mark Swieter, PhD, Chief, 

Training and Special Projects Review Branch, 

Office of Extramural Affairs, National 

Institute on Drug Abuse, NIH, DHHS, Suite 

220, 6101 Executive Boulevard, Bethesda, 

MD 20892–8401, (301) 435–1389. 

ms80x@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS). 

Dated: June 13, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3012 Filed 6–19–07; 8:45 am] 

BILLING CODE 4140-–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of 

ClosedMeetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, T–Cell Immunology. 

Date: July 10, 2007. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 


rwilkins on PROD1PC63 with NOTICES